PFE Pfizer Inc.

Range, yield & payout streak

Based on Yahoo annual dividend totals through 2025 (excludes incomplete 2026).

BDC / cash pass-through vs ordinary dividend

Ordinary corporate dividend — paid from corporate earnings/cash at the board’s discretion. Unlike BDCs/REITs, there is usually no pass-through distribution mandate. Coverage (earnings/FCF vs dividend), balance sheet, and streak matter more than yield height.

Remember: high yield ≠ safer. Pass-through vehicles (BDC / REIT) can show high distributions by design while carrying credit, rate, or occupancy risk.

Dividend safety rating

High yield ≠ safer — elevated yield often prices higher risk or return-of-capital. Payout streak (non-decreasing annual totals): ~16 years. Yahoo payoutRatio raw=2.2632 (interpret cautiously). Yield ~6.21% is above typical ordinary-corporate averages; verify coverage.

Dividend history trend (recent payments)

Sourced from Yahoo via yfinance. Gaps or missing rows = data unavailable, not zeroes we invented.

Pass-through / BDC mechanics (deeper)

Ordinary corporate dividend — paid from corporate earnings/cash at the board’s discretion. Unlike BDCs/REITs, there is usually no pass-through distribution mandate. Coverage (earnings/FCF vs dividend), balance sheet, and streak matter more than yield height.

Advanced frame: for ordinary payers, focus on earnings/FCF coverage and balance-sheet flexibility. For REITs, focus on AFFO/FFO trends, occupancy, and debt ladders. For BDCs, focus on NII vs distribution, non-accruals, leverage vs statutory limits, and NAV drift. This page still is not a Crystal Signals entry card — no Counsel fire / manage stamp here.

Full company blurb

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.